{"nctId":"NCT00546351","briefTitle":"Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.","startDateStruct":{"date":"2004-05"},"conditions":["Painful Diabetic Neuropathy"],"count":621,"armGroups":[{"label":"Lacosamide","type":"EXPERIMENTAL","interventionNames":["Drug: Lacosamide"]}],"interventions":[{"name":"Lacosamide","otherNames":["Vimpat"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who completed Study SP743 (NCT00238524) or SP874 (NCT00350103) and, in the investigator's opinion, might benefit from long-term administration of SP746 (NCT00546351). Exception: subjects who prematurely discontinued\n* SP743 (NCT00238524) or SP874 (NCT00350103) due to lack of efficacy or due to intolerability to trial medication (after Visit 5but prior to entering the Maintenance Phase) may be eligible to participate in SP746 (NCT00546351), after consultation with the medical monitor\n\nExclusion Criteria:\n\n* Subject has clinically relevant ECG abnormalities, or a QTc interval ≥500 ms, and/or a QTc interval increase of ≥60 ms from the mean pre-dose QTc value at Visit 2 of SP743 (NCT00238524) or SP874 (NCT00350103)\n* Subject has aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥3 times the upper limit of the normal range (ULN) with total bilirubin ≥2 times ULN or transaminases (AST and/or ALT) ≥5 times ULN\n* Subject has a clinically relevant medical condition that, in the opinion of the investigator, jeopardizes or compromises the subject's ability to participate in this trial\n* Subject is a pregnant or nursing female, or is of childbearing potential and is not surgically sterile, 2 years postmenopausal, or does not practice 2 combined methods of contraception","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).","description":"Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"416","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).","description":"A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:\n\n* Is fatal\n* Is life-threatening\n* Results in persistent or significant disability/incapacity\n* Requires inpatient hospitalization\n* Prolongs existing inpatient hospitalization\n* Is a congenital anomaly/birth defect\n* Is considered to be an important medical event. Such an event may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definitions above","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Baseline Visit.","description":"On the Likert Scale, 0 = no pain and 10 = worst possible pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.45","spread":"1.371"}]}]}]},{"type":"SECONDARY","title":"Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Last Visit.","description":"On the Likert Scale, 0 = no pain and 10 = worst possible pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":"2.246"}]}]}]},{"type":"SECONDARY","title":"Average Pain Score as Measured by a 100 mm Visual Analog Scale (VAS) at Baseline.","description":"Visual Analog Scale (VAS) 0 mm = no pain and 100 mm = worst possible pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.83","spread":"15.986"}]}]}]},{"type":"SECONDARY","title":"Average Pain Score as Measured by a 100 mm Visual Analogue Scale (VAS) at Last Visit.","description":"On VAS 0 mm = no pain and 100 mm = worst possible pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.47","spread":"23.940"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Impression of Change (PGIC) at Last Visit.","description":"The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse \\[score of 1\\] to much better \\[score of 7\\]).\n\nReported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Intensity at Last Visit.","description":"0 = no pain and 10 = most intense pain sensation imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"2.38"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sharpness at Last Visit.","description":"0 = not sharp and 10 = most sharp sensation imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"2.23"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Heat at Last Visit.","description":"0 = not hot and 10 = the most hot sensation imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Cold at Last Visit.","description":"0 = not cold and 10 = the coldest sensation imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.19"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Dullness at Last Visit.","description":"0 = not dull and 10 = most dull sensation imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Unpleasantness at Final Visit.","description":"0 = not unpleasant and 10 = most unpleasant sensation imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"2.24"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Surface Pain at Last Visit.","description":"0 = no surface pain and 10 = most intense surface pain imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"2.17"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Deep Pain at Last Visit.","description":"0 = no deep pain and 10 = most intense deep pain imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"2.39"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Itchiness at Final Visit.","description":"0 = not itchy and 10 = most itchy sensation imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"2.06"}]}]}]},{"type":"SECONDARY","title":"Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sensitivity at Last Visit.","description":"0 = not sensitive and 10 = most sensitive sensation imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"2.31"}]}]}]},{"type":"SECONDARY","title":"Average Pain Interference With Sleep (11-point Likert Scale) at Baseline.","description":"0 = no interference with sleep and 10 = worst possible interference with sleep.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.98","spread":"1.850"}]}]}]},{"type":"SECONDARY","title":"Average Pain Interference With Sleep (11-point Likert Scale) at Last Visit.","description":"0 = no interference with sleep and 10 = worst possible interference with sleep.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":"2.281"}]}]}]},{"type":"SECONDARY","title":"Average Pain Interference With Activity (11-point Likert Scale) at Baseline.","description":"0 = no interference with activity and 10 = worst possible interference with activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.11","spread":"1.660"}]}]}]},{"type":"SECONDARY","title":"Average Pain Interference With Activity (11-point Likert Scale) at Last Visit.","description":"0 = no interference with activity and 10 = worst possible interference with activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":"2.349"}]}]}]},{"type":"SECONDARY","title":"Average Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) at Baseline.","description":"The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":"8.04"}]}]}]},{"type":"SECONDARY","title":"Average Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) at Last Visit.","description":"The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":"9.41"}]}]}]},{"type":"SECONDARY","title":"Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Baseline.","description":"The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8","spread":"11.04"}]}]}]},{"type":"SECONDARY","title":"Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Last Visit.","description":"The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.5","spread":"10.90"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":132,"n":621},"commonTop":["Nasopharyngitis","Dizziness","Hypertension","Headache","Vertigo"]}}}